We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Effects of a Genistein Concentrated Polysaccharide (GCP) for Prostate Cancer on Active Surveillance. (GCP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00584532
Recruitment Status : Completed
First Posted : January 2, 2008
Last Update Posted : January 2, 2008
Information provided by:

Study Description
Brief Summary:
Genistein Combined Polysaccharide (GCP) may play a role as a secondary chemopreventive agent in the treatment of localized prostate cancer.

Condition or disease Intervention/treatment Phase
Prostate Cancer Drug: Placebo Drug: GCP - Genistein Combined Polysaccharide Phase 2 Phase 3

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 66 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Effects of a Genistein Concentrated Polysaccharide (GCP) on Patients With a Diagnosis of Prostate Cancer on Active Surveillance.
Study Start Date : November 2003
Primary Completion Date : December 2005
Study Completion Date : December 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer
Drug Information available for: Genistein
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Placebo Comparator: A
A=Placebo ARM of Study
Drug: Placebo
10 Placebo Capsules taken orally every day.
Other Name: Placebo capsules (contain cellulose only)
Active Comparator: B
B=GCP Capsules. Ten 500 mg capsules per day for a total of 5 grams a day.
Drug: GCP - Genistein Combined Polysaccharide
Ten 500 mg capsules given orally per day. Total of 5 grams per day per patient.

Outcome Measures

Primary Outcome Measures :
  1. Decrease in PSA levels in men on GCP [ Time Frame: 6 Months ]

Secondary Outcome Measures :
  1. Increased PSA Doubling Time (PSADT)in men on GCP. [ Time Frame: 6 Months ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Participants must be male and have a pathological diagnosis of prostate cancer
  • Pathological diagnosis of prostate cancer must be confirmed and on file with CRA prior to study entry.
  • No treatment (surgery, radiation, or hormones) prior to study entry.
  • PSA between 2.0 and 10.0 ng/ml.
  • If PSA is >10.0, patient must have been on Active Surveillance for 12 months prior to study initiation.
  • No known allergy to soy or soy products.
  • The patient is not currently taking more than 2 grams of genistein a day in nutritional or diet enhancing supplements (OTC supplements).
  • Participant has not been on any previous GCP clinical trial.
  • Normal Chemistry values prior to study entry.

Exclusion Criteria:

  • No pathological documentation of prostate cancer.
  • Prior treatment for prostate cancer.
  • PSA >10.0 ng/ml but not on Active Surveillance for 12 months.
  • Allergy to soy or soy products.
  • Abnormal chemistry values.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00584532

Sponsors and Collaborators
University of California, Davis
Principal Investigator: Robert Hackman, MD University of California, Davis - Dept. of Nutrition
More Information

Responsible Party: Robert Hackman, PhD, University of California, Davis - Department of Nutrition
ClinicalTrials.gov Identifier: NCT00584532     History of Changes
Other Study ID Numbers: 200412146-5
First Posted: January 2, 2008    Key Record Dates
Last Update Posted: January 2, 2008
Last Verified: December 2007

Keywords provided by University of California, Davis:

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Anticarcinogenic Agents
Protective Agents
Physiological Effects of Drugs
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Estrogens, Non-Steroidal
Hormones, Hormone Substitutes, and Hormone Antagonists